Details

Autor(en) / Beteiligte

• Ryan, Charles J
• Smith, Matthew R
• de Bono, Johann S
• Molina, Arturo
• Logothetis, Christopher J
• de Souza, Paul
• Fizazi, Karim
• Mainwaring, Paul
• Piulats, Josep M
• Ng, Siobhan
• Carles, Joan
• Mulders, Peter F.A
• Basch, Ethan
• Small, Eric J
• Saad, Fred
• Schrijvers, Dirk
• Van Poppel, Hendrik
• Mukherjee, Som D
• Suttmann, Henrik
• Gerritsen, Winald R
• Flaig, Thomas W
• George, Daniel J
• Yu, Evan Y
• Efstathiou, Eleni
• Pantuck, Allan
• Winquist, Eric
• Higano, Celestia S
• Taplin, Mary-Ellen
• Park, Youn
• Kheoh, Thian
• Griffin, Thomas
• Scher, Howard I
• Rathkopf, Dana E

Titel

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Ist Teil von

• The New England journal of medicine, 2013-01, Vol.368 (2), p.138-148

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant improvement in progression-free survival with abiraterone as first-line chemotherapy in these patients. Metastatic castration-resistant prostate cancer, defined by tumor growth despite a testosterone level of less than 50 ng per deciliter (1.7 nmol per liter), causes approximately 258,400 deaths annually worldwide. 1 , 2 Death of patients with this condition, which typically occurs within 24 to 48 months after the onset of castration resistance, is commonly preceded by a sequence of landmark events associated with deterioration of overall health and worsening symptoms (Figure S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). 3 – 7 Among the treatment options for patients with metastatic castration-resistant prostate cancer who have not undergone chemotherapy . . .